GRCE Quote, Financials, Valuation and Earnings

Oragenics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

Grace Therapeutics has a consensus price target of $11.88, signalling upside risk potential of 493.9%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 434.19%. Given that Grace Therapeutics has higher upside potential than Oragenics, analysts believe Grace Therapeutics is more attractive than Oragenics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is lower than Oragenics's net income of -$3.3M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 1.17x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Grace Therapeutics's net margin of -2357.27%. Grace Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Grace Therapeutics has a consensus price target of $11.88, signalling upside risk potential of 493.9%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that Palatin Technologies has higher upside potential than Grace Therapeutics, analysts believe Palatin Technologies is more attractive than Grace Therapeutics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Grace Therapeutics's net income of -$4.2M is lower than Palatin Technologies's net income of -$2.4M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -- compared to Grace Therapeutics's net margin of -125.59%. Grace Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -46.69%.

Grace Therapeutics has a consensus price target of $11.88, signalling upside risk potential of 493.9%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 86.43%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $61.5M. Grace Therapeutics's net income of -$4.2M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 15.13x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Grace Therapeutics has a consensus price target of $11.88, signalling upside risk potential of 493.9%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 455.56%. Given that Grace Therapeutics has higher upside potential than Theriva Biologics, analysts believe Grace Therapeutics is more attractive than Theriva Biologics.

Grace Therapeutics has a beta of 1.327, which suggesting that the stock is 32.655% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is higher than Theriva Biologics's net income of -$4.4M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.